Skip to main content
. 2024 Jan 11;80:101880. doi: 10.1016/j.molmet.2024.101880

Figure 4.

Figure 4

Combined ActRII blockade plus GLP-1 receptor agonism improves circulating markers of adipose inflammation and function.

A) Ad libitum blood glucose levels from HFD-fed mice.

B) Ad libitum plasma insulin levels from HFD-fed mice. Values below the limit of detection were given the concentration value of 0.1 ng/mL and marked in red.

C) Serum adiponectin levels from HFD-fed mice (n = 5).

D) Serum leptin levels from HFD-fed mice (n = 5).

E) Serum IL-6 levels from HFD-fed mice (n = 5).

F) Serum MCP1 levels from HFD-fed mice (n = 5).

G) Serum glycerol levels from HFD-fed mice.

H) Serum NEFA levels from HFD-fed mice.

n = 8 mice for control and semaglutide + bimagrumab groups, n = 9 mice for semaglutide and bimagrumab groups unless otherwise indicated. ∗p < 0.05, ∗∗p < 0.001, ∗∗∗p < 0.0005, ∗∗∗∗p < 0.0001 for control vs. bimagrumab, semaglutide, and semaglutide + bimagrumab; #p < 0.05, ##p < 0.001, ###p < 0.0005, ####p < 0.0001 for bimagrumab vs. semaglutide and semaglutide + bimagrumab; & p < 0.05, && p < 0.001 for semaglutide vs. semaglutide + bimagrumab.